A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs MK-1697 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.
- 20 Jun 2018 Planned initiation date changed from 4 Jun 2018 to 10 Aug 2018.
- 08 May 2018 New trial record